Card image cap
COPD Foundation, ENA tie-up for antiviral nasal spray

ENA Respiratory, an Australian clinical stage drug researcher, has collaborated with the COPD Foundation, a nonprofit with a mission to improve the lives of those affected by COPD and other lung conditions, to develop its first-in-class, broad-spectrum antiviral nasal spray — known as INNA-051 — for populations at risk of developing complications from respiratory viral infections, including COVID-19. INNA-051 is a potent activator of the innate immune system, which is delivered as a spray to the nasal cavity, and that the antiviral therapy can be given before or after an infection sets in. ENA also plans to conduct a phase 2 trial to confirm the antiviral potential of INNA-051 in up to 423 adults who had household contact with an individual with a confirmed SARS-CoV-2 infection.

Content by Future Medicine

Disclaimer :
The author(s)' thoughts and opinions in this article are their own and do not necessarily reflect DocMode's viewpoint. The article is in no way created or edited by DocMode.

Supported by Koye Pharmaceuticals

Submit a Comment